PATHFINDER: Accelerating the lung cancer patient pathway

Overview

The UK have some of the lowest global survival rates for lung cancer.


Early diagnosis is critical for patients to be able to access AstraZeneca’s life-saving, innovative products and improve outcomes, but NHS workers do not have capacity to address this challenge on a systematic scale.


Regional heterogeneity in care is impacting efficacy of lung cancer services. Impactful change requires engagement from the NHS, which will support initiatives to develop and test new models of care

Challenge

PATHFINDER was a collaborative initiative between the NHS, AstraZeneca and IQVIA aiming to support the NHS in understanding current patient pathways and implementing changes to facilitate earlier diagnosis of lung cancer.

  • Analysis of quantitative and qualitative data, to identify pain points in patient pathways
  • Deep-dive assessments in centres to identify local needs and develop action plans
  • Implementation of key recommendations, to streamline pathways

Re-engineering the National Lung Cancer Best Practice Pathway:


Working with the NHS National Lung Cancer team, IQVIA played a pivotal role in improving lung cancer care pathways, providing a roadmap to help NHS Hospitals deliver treatment faster, reducing patient review times.


Pathfinder will help the NHS achieve the goal to diagnose 75% of all cancer patients at stage I/II by 2028.

Measureable optimisation of care pathways

Implementing optimised pathway steps identified through pathfinder nationally could release or 2,430 days of capacity if patients were treated within 21 days.

PATHFINDER is providing a roadmap to help trusts deliver treatment faster, helping to reach these targets

Patient review times reduced: 5 days < 24 hours

PET-CT scan wait time reduce: 5-7 days < 2 days

Improved sample collection & delivery: 80% now reach lab on same day

2 findings incorporated into GRIFT facilitating improved MDT working


Future opportunities to disseminate findings across the cancer clinical community, allowing solutions to be leveraged across other centres and other cancer areas

Headline Heading 2

Body text area. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur at orci in eros blandit fermentum eu eget nulla. Vestibulum ornare felis metus. Quisque efficitur lorem ut justo ornare laoreet. Proin blandit dui consectetur malesuada vehicula. Morbi consequat eros dolor, ut tristique ex aliquet ac. Suspendisse posuere pulvinar purus, sed tempor magna eleifend sit amet. Mauris viverra tincidunt ligula, at porta ex mollis eget. Integer nec lacus faucibus nisi bibendum accumsan. Cras tristique est nec est semper volutpat. Interdum et malesuada fames ac ante ipsum primis in faucibus. Mauris neque arcu, blandit vitae velit quis, finibus cursus justo. Etiam eu ante turpis. Nunc ac nisl scelerisque, iaculis justo et, semper quam. Aenean vestibulum condimentum leo.

  • Sit amet, consectetur adipiscing elit
  • Nullam ornare nisi in tristique cursus
  • Morbi non sem sit amet nulla scelerisque tincidunt
Study
Participants

This Study Does XYZ

Morbi consequat eros dolor, ut tristique ex aliquet ac. Suspendisse posuere pulvinar purus, sed tempor magna eleifend sit amet. Mauris viverra tincidunt ligula, at porta ex mollis eget. Integer nec lacus faucibus nisi bibendum accumsan. Cras tristique est nec est semper volutpat. Interdum et malesuada fames ac ante ipsum primis in faucibus. Mauris neque arcu, blandit vitae velit quis, finibus cursus justo. Etiam eu ante turpis. Nunc ac nisl scelerisque, iaculis justo et, semper quam. Aenean vestibulum condimentum leo.

Vestibulum blandit ultricies elit ullamcorper tincidunt

Nullam ultrices a nulla ac maximus. Fusce posuere sollicitudin mauris, et blandit libero lacinia et. Donec lacinia iaculis rhoncus. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Phasellus sagittis ultricies tortor, sed pretium felis dictum ut. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut sollicitudin diam nec diam vehicula, efficitur facilisis metus gravida. Maecenas id nibh urna. Aliquam et enim eget dui elementum sodales ac eget augue. Cras at purus diam. Nam est risus, condimentum et ultrices volutpat, congue et nulla. Mauris scelerisque eros in lacinia auctor. Aenean vestibulum turpis at velit auctor finibus eu in felis. Nunc sollicitudin lorem sit amet risus eleifend porttitor.
Headline
Nulla gravida nisi et pulvinar aliquet. Fusce mattis pellentesque rhoncus. Ut nec quam a odio cursus bibendum in ac ante. Nam non purus placerat, molestie metus ut, gravida turpis. Aenean justo mauris, tristique ac ex et, faucibus viverra metus. Nulla turpis ipsum, gravida et tempus sit amet, lacinia at lectus. Nulla hendrerit, erat sed blandit tincidunt, velit magna elementum ante, sed feugiat nisi dui rhoncus elit. Donec ligula quam, eleifend non luctus at, accumsan eget libero. Sed tristique, orci at pellentesque dapibus, sem lorem dapibus enim, nec rutrum urna purus ut dui.
smaller group discussion

Eyebrow Text

Headline Appears Here

Proinarc umi tempor vitae venenatis non, elementum lobortis neque. Vestibulum blandit ultricies elit ullamcorper tincidunt. Phasellus at aliquam arcu. Phasellus sem nibh, mattis id ultricies nec, consectetur nec odio. Ut ac enim et purus auctor accumsan. Fusce id tincidunt purus. Sed vel tristique nulla. Praesent pellentesque leo at augue porta, et lobortis ipsum lobortis. Pellentesque scelerisque semper mauris, in accumsan nibh sollicitudin vel.

Multi-Source Brand Discovery

Eyebrow Text

Contact Us